I enjoy creating and spreading knowledgeable content for everyone around the world and try my best not to leave even the smallest of mistakes go unnoticed.
Speaking with derek leroith md phd live from the 2007 ada
Derek LeRoith, M.D., Ph.D is an endocrinologist and Professor of Medicine and the current Chief of the Hilda and J. Lester Gabrilove, M.D. Division of Endocrinology, Diabetes and Bone Disease and Director of the Metabolism Institute of the Mount Sinai Medical Center in New York City. He is an international expert in insulin-like growth factor-1 (IGF-1).
LeRoith was the first to demonstrate the link between insulin-like growth factor-1 (IGF-1) and cancer and is the current recipient of an NCI grant to study the relationship between cancer and type 2 diabetes. He is the author of more than 500 publications and an editor of more than 20 textbooks on endocrinology.
Symposium on diabetes and obesity derek leroith md phd
Biography
LeRoith was born in 1945 in South Africa. He earned both his M.B. Ch.B. and his Ph.D. from the University of Cape Town. In 1974, he became a fellow of the College of Physicians of South Africa, and, in 1975, he became a member of the Royal College of Physicians of the United Kingdom. His post-doctoral training included a residency in pediatrics at the Kaplan Medical Center in Rehovot, Israel, an endocrine research fellowship at the University of Cape Town, and a residency in medicine and geriatrics at Middlesex Hospital in London.
1996 British Endocrine Society Transatlantic Medal
1996 The Herman O. Mosenthal Memorial Lecture
2004 The Yogesh C. Patel Memorial Lecture
2008 Dell Fisher Visiting Professor, UCLA
Books
Partial list:
Diabetes Mellitus: a Fundamental and Clinical text, Derek LeRoith (Editor), Simeon I. Taylor (Editor) and Jerrold M Olefsky (Editor), 2003 (Third Edition), ISBN 0-7817-4097-5
Molecular Biology of Diabetes, Part I: Autoimmunity and Genetics; Insulin Synthesis and Secretion, Boris Draznin (Editor), Derek LeRoith (Editor), 1994, ISBN 0-89603-286-8
Molecular Biology of Diabetes, Part II: Insulin Action, Effects on Gene Expression and Regulation, and Glucose Transport, Boris Draznin (Editor), Derek LeRoith (Editor), 1994, ISBN 0-89603-287-6
Insulin-like Growth Factors: Molecular and Cellular Aspects, Derek LeRoith (Author), 1991, ISBN 0-8493-5712-8
Controversies in Treating Diabetes: Clinical and Research Aspects (Contemporary Endocrinology), Derek LeRoith (Editor), Aaron I. Vinik (Editor), 2008, ISBN 1-58829-708-X
Publications
Partial list:
Insulin sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, Leroith D. Diabetes. 3 December 2009. doi:10.2337/db09-1291 PMID 19959755
High-efficient FLPo deleter mice in C57BL/6J background. Wu Y, Wang C, Sun H, LeRoith D, Yakar S. PLoS One. 26 November 2009;4(11):e8054. doi:10.1371/journal.pone.0008054 PMID 19956655
Pediatric endocrinology: Part II. Foreword. LeRoith D. Endocrinol Metab Clin North Am. 2009 Dec;38(4):xi-xiii. doi:10.1016/j.ecl.2009.09.006 PMID 19944284
Biological effects of growth hormone on carbohydrate and lipid metabolism. Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, Leroith D. Growth Horm IGF Res. 30 September 2009. doi:10.1016/j.ghir.2009.09.002 PMID 19800274
Pediatric endocrinology: part I. Foreword. Leroith D. Endocrinol Metab Clin North Am. 2009 Sep;38(3):xi-xiii. doi:10.1016/j.ecl.2009.07.004 PMID 19716998
Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation. Novosyadlyy R, Vijayakumar A, Lann D, Fierz Y, Kurshan N, LeRoith D. Oncogene. 1 October 2009;28(39):3477-86. Epub 20 July 2009. doi:10.1038/onc.2009.209 PMID 19617901
Gender differences in metabolic disorders. LeRoith D. Gend Med. 2009;6(Suppl 1):1-3. doi:10.1016/j.genm.2009.02.003 PMID 19318215
Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-1 null mice. Wu Y, Sun H, Yakar S, LeRoith D" Endocrinology 2009 Sep;150(9):4395-403. Epub 4 June 2009. doi:10.1210/en.2009-0272 PMID 19497975
Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus. Kawashima Y, Chen J, Sun H, Lann D, Hajjar RJ, Yakar S, Leroith D" Diabetologia 2009 Jul;52(7):1434-41. Epub 13 May 2009. doi:10.1007/s00125-009-1378-8 PMID 19436992
Basic aspects and clinical applicability in the field of lipidology. Foreword. LeRoith D. Endocrinol Metab Clin North Am. 2009 Mar;38(1):xiii-xv. doi:10.1016/j.ecl.2009.01.015 PMID 19217508
Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Kawashima Y, Fritton JC, Yakar S, Epstein S, Schaffler MB, Jepsen KJ, LeRoith D" Bone 2009 Apr;44(4):648-55. Epub 24 December 2008. doi:10.1016/j.bone.2008.12.012 PMID 19150422
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Hong SH, Briggs J, Newman R, Hoffman K, Mendoza A, LeRoith D, Helman L, Yakar S, Khanna C. Int J Cancer. 1 May 2009;124(9):2042-9. doi:10.1002/ijc.24169 PMID 19132750
Rationale and strategies for early detection and management of diabetic kidney disease. Radbill B, Murphy B, LeRoith D. Mayo Clin Proc. 2008 Dec;83(12):1373-81. Review. doi:10.1016/S0025-6196(11)60786-6 PMID 19046557
The role of endocrine insulin-like growth factor-I and insulin in breast cancer. Lann D, LeRoith D. J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):371-9. Epub 22 November 2008. Review. doi:10.1007/s10911-008-9100-x PMID 19030972